Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients

Annals of Hematology

Volumn 91, Issue 9, 2012, Pages 1443-1449

  Cassinerio, Elena ^a   Roghi, Alberto ^b   Pedrotti, Patrizia ^a   Brevi, Francesca ^a   Zanaboni, Laura ^a   Graziadei, Giovanna ^a   Pattoneri, Paolo ^b   Milazzo, Angela ^b   Cappellini, Maria Domenica ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Cardiac function; Cardiac magnetic resonance T2*; Chelation therapy; Myocardial siderosis; Thalassemia major

Indexed keywords

ANTIHISTAMINIC AGENT; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; IRON;

ADULT; AGRANULOCYTOSIS; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG WITHDRAWAL; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HUMAN; IRON CHELATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THALASSEMIA MAJOR;

ADULT; BENZOIC ACIDS; BETA-THALASSEMIA; COMORBIDITY; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEART; HEART FAILURE; HUMANS; IRON CHELATING AGENTS; MALE; MYOCARDIUM; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; PYRIDONES; STROKE VOLUME; TRIAZOLES; YOUNG ADULT;

EID: 84864932660     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1480-8     Document Type: Article

References (22)

1. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A (2004) Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89:1187-1193
2. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tuker EE, Allen CJ, Farrell DE, Harris JW (1994) Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 331:567-573
3. Cappellini MD, Musallam KM, Taher AT (2009) Overview of iron chelation therapy with deferoxamine and deferiprone. Hemoglobin 33(suppl1):S58-69
4. Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardetto F, Filosa A, Magnano C, Caruso V, Gerardi C, Argento C, Campisi S, Cantella F, Commendatore F, D'Ascola DG, Fidara C, Ciancio A, Galati MC, Giuffrida G, Cingari R, Giugno G, Lombardo T, Prossamariti I, Malizia R, Meo A, Roccamo G, Romeo MA, Violi P, Cianciulli P, Rigano P (2009) Improving survival with deferiprone treatment in patients with thalassemia major: a prospective, multicenter, randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cell Mol Dis 42(3):247-251
5. Pontikoglou C, Papadaki HA (2010) Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone. Hemoglobin 34 (3):291-304
6. CappelliniMD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina P, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D (2006) A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator in patients with β-thalassemia. Blood 107(9):3455-3462
7. Pennell D, Porter JB, Cappellini MD, El-Beshlawy A, Chan LL, Aydinok Y, ElalfyMS, Sutcharitchan P, Li CK, IbrahimH, Viprakasit V, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A (2008) Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia. Blood 115(12):2364-71
8. Pennell D, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy MS, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A (2011) Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Hematologica 96(1):48-54
9. Wood JC (2009) History and current impact of cardiac magnetic resonance imaging on the management of iron overload. Circulation 120:1937-1939
10. Westwood MA, Firmin DN, Gildo M, Renzo G, Stathis G, Markissia K, Vasili B, Pennel DJ (2005) Intercentre reproducibility of magnetic resonance T2* measurements of myocardial iron in thalassaemia. Int J Cardiovasc Imaging 21:531-538
11. Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, Wu D, Taylor J, Westwood MA, Andreson LJ, Pennel DJ (2009) Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 120:1961-1968
12. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R (2006) Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 107:3738-3744
13. Wood JC, Kang BP, Thompson A, Giardina P, Harmatz P, Glynos T, Paley C, Coates TD (2010) The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood 116(4):537-543
14. Taher A, El-Beshlawy A, Elalfy MS, Alzir K, Daar S, Habr D, Krieulier-Krahn U, Hmissi A, Al Jefri A (2009) Efficacy and safety of deferasirox, an oral iron chelator, in heavily ironoverloaded patients with β-thalassaemia: the ESCALATOR study. Eur J Haematol 82(6):458-465
15. Pepe A, Meloni A, Capra M, Cianciulli P, Prossomariti L, Malaventura C, Putti MC, Lippi A, Romeo MA, Bisconte MG, Filona A, Caruso V, Quarta A, Pitrolo L, Missere M, Midiri M, Rossi G, Positano V, Lombardi M, Maggio A (2011) Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function determined by quantitative magnetic resonance imaging. Heamatologica 96(1):41-47
16. Thalassemia International Federation (2007) Guidelines for the clinical management of thalassaemia 2nd ed.
17. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, GamberiniMR, Ghilardi R, Piga A, RomeoMA, Zhao H, Cnaan A (2006) Cardiacmorbidity andmortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 107 (9):3733-3738
18. Derchi G, Formisano F, Balocco M, Galanello R, Bina P, Dessì C, Piga A, Donato G, Cappellini MD, Cassinerio E, Quarta G, Melpignano A, Forni GL (2011) Clinical management of cardiovascular complications in patients with thalassemia major: a large observational multicenter study. Eur J Echocard 12(3):242-246
19. Davis BA, Porter JB (2000) Long-term outcome of continuous 24- hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 95:1229-1236
20. Lai ME, Grady RW, Vacquer S, Pepe A, Carta MP, Bina P, Sau F, Cianciulli P, Maggio A, Galanello R, Farci P (2010) Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone. Blood Cell Mol Dis 45:136-139
21. Aessopos A, Fragodimitri C, Karabatsos F et al (2007) Cardiac magnetic resonance imaging R2* assessment and analysis of historical parameters in patients with transfusion-dependent thalassemia. Haematologica 92(1):131-132
22. Chouliaras GL, Kattamis A, Berdoukas V, Gotsis ED, Mavrogeni S, Ladis V (2010) Cardiac magnetic resonance in transfusion dependent thalassemia: assessment of iron load and relationship to left ventricular ejection fraction. Br J Haematol 151:397-401